Clinical Trials

200 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Neuroblastoma, Pheochromocytoma

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT03839498 2026-03-02

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Phase 2 Active not recruiting

6 enrolled

Phase 2 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT03946527 2026-03-02

LAMPARA

10 enrolled

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma

NCT05636540 2026-02-27

In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma

30 enrolled

Paraganglioma, Pheochromocytoma

NCT01022515 2026-02-06

PHEO

60 enrolled

Phase 2 Active not recruiting

Essential Hypertension, Hypertension, Paraganglioma, Pheochromocytoma

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

157 enrolled 26 charts

CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT01850888 2025-12-18

MIBG for Refractory Neuroblastoma and Pheochromocytoma

15 enrolled

Neuroblastoma, Pheochromocytoma

NCT07288931 2025-12-17

Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma

Phase NA Recruiting

40 enrolled

Phase EARLY_PHASE1 Active not recruiting

Paraganglioma, Pheochromocytoma

NCT03541720 2025-12-03

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

13 enrolled

Neuroblastoma, Pheochromocytoma

NCT07167329 2025-09-11

BELIEVE-VHL

CNSEndocrineGenitourinary

100 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

CNSDermatologicEndocrineGenitourinarySarcoma

400 enrolled

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT02302833 2025-07-31

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

21 enrolled 7 charts

Paraganglioma, Pheochromocytoma

NCT06377033 2025-07-20

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Phase NA Recruiting

1,000 enrolled

Alzheimer Disease, Paraganglioma, Parkinson Disease, Pheochromocytoma, Polyneuropathies, Aortic Aneurysm, Thoracic, Genetic Predisposition to Disease, Frontotemporal Dementia

NCT04400474 2025-06-19

CABATEN

CNSEndocrineHead & NeckNET

93 enrolled 17 charts

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

NCT05702944 2025-06-12

The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma

Phase 4 Recruiting

24 enrolled

EndocrineGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Paraganglioma, Pheochromocytoma

NCT05944237 2025-06-08

HTL0039732 in Participants With Advanced Solid Tumours

Phase 1/2 Recruiting

150 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06429397 2025-04-29

Anlotinib Combined With Benmelstobart for Advanced Pheochromocytoma

Phase 2 Not yet recruiting

22 enrolled

Pheochromocytoma

NCT00843037 2024-10-17

SNIPP

25 enrolled 19 charts

Neoplasm Metastasis, Paraganglioma, Pheochromocytoma

NCT01379898 2024-09-19

PRESCRIPT

Phase 4 Completed

134 enrolled

DermatologicEndocrineGenitourinaryThoracic

Pheochromocytoma

NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Phase 1 Completed

96 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

NCT06045260 2024-08-13

LUFOR

100 enrolled

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04860700 2024-06-12

The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma

27 enrolled

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT04605848 2024-05-09

MICROBAT

Phase NA Terminated

7 enrolled

Phase EARLY_PHASE1 Recruiting

Paraganglioma, Pheochromocytoma

NCT05069220 2024-03-01

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

150 enrolled

Neuroblastoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT03008369 2024-02-20

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

3 enrolled 9 charts

Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT03176693 2023-11-20

Preoperative Alpha Blockade for Pheochromocytoma

Phase 3 Completed

39 enrolled 8 charts

Paraganglioma, Pheochromocytoma

NCT06037135 2023-10-06

Dexmedetomidine Infusion During Laparoscopic Adrenalectomy

40 enrolled

Pheochromocytoma

NCT03986593 2023-07-05

Cryoablation of Bone Metastases From Endocrine Tumors

Phase NA Terminated

17 enrolled

EndocrineHead & NeckNET

Adrenal Gland Neoplasms, Neoplasm Metastasis, Pheochromocytoma, Thyroid Neoplasms, Neuroendocrine Tumors

NCT05885399 2023-06-02

The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic Treatment

5 enrolled

Neoplasm Metastasis, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05885386 2023-06-01

A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL

20 enrolled

Paraganglioma, Pheochromocytoma

NCT05883085 2023-05-31

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

10 enrolled

Paraganglioma, Pheochromocytoma

NCT05858177 2023-05-15

MPPGL

62 enrolled

Neoplasm Metastasis, Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT05803330 2023-04-07

Study of Alpha-blockers Alone During Preoperative Preparation in Patients With Pheochromocytoma

95 enrolled

Pheochromocytoma

NCT02186678 2023-04-06

DOTATATE

30 enrolled

Paraganglioma, Pheochromocytoma

NCT00442533 2023-04-03

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Phase 2/3 Completed

200 enrolled

CNSDermatologicEndocrineNET

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Somatostatinoma, Neuroendocrine Tumors

NCT04276597 2023-03-10

PUTNET

Phase 2 Withdrawn

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT05133349 2021-11-24

EASOAIPPGL

20 enrolled

Paraganglioma, Pheochromocytoma

NCT04320589 2021-09-01

the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma

30 enrolled

Pheochromocytoma

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

Phase 1/2 Withdrawn

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00843531 2020-09-29

RAD001 and Erlotinib in Patients With Neuroendocrine Tumors

Phase 2 Terminated

17 enrolled 10 charts

Carcinoid Tumor, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Phase 2 Withdrawn

CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

NCT03344016 2020-07-09

MUPPET

Phase NA Recruiting

1,148 enrolled

Paraganglioma, Pheochromocytoma

NCT01635907 2020-04-14

Dovitinib in Neuroendocrine Tumors

8 enrolled

Paraganglioma, Pheochromocytoma

NCT02672020 2019-09-24

COMETETACTIC

448 enrolled

Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

50 enrolled 7 charts

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT01676025 2017-10-06

PRA

83 enrolled

DermatologicEndocrineGastrointestinalNET

Adrenal incidentaloma, Adrenal Gland Diseases, Cushing Syndrome, Hyperaldosteronism, Pheochromocytoma

NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Phase 1 Withdrawn

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

NCT02618694 2017-03-03

PostLapAdrnl

13 enrolled